CA2675511A1 - N-aryl pyrazole compounds for use against diabetes - Google Patents

N-aryl pyrazole compounds for use against diabetes Download PDF

Info

Publication number
CA2675511A1
CA2675511A1 CA002675511A CA2675511A CA2675511A1 CA 2675511 A1 CA2675511 A1 CA 2675511A1 CA 002675511 A CA002675511 A CA 002675511A CA 2675511 A CA2675511 A CA 2675511A CA 2675511 A1 CA2675511 A1 CA 2675511A1
Authority
CA
Canada
Prior art keywords
alkyl
methyl
aryl
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002675511A
Other languages
English (en)
French (fr)
Inventor
Yasuyuki Ogawa
Ryo Okuyama
Satoshi Shibuya
Narihiro Toda
Zhaodan Cao
Zice Fu
Xiaolin Hao
Yong-Jae Kim
Leping Li
Sarah E. Lively
Mike Lizarzaburu
Hui Tian
Ming Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2675511A1 publication Critical patent/CA2675511A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002675511A 2006-10-10 2007-10-09 N-aryl pyrazole compounds for use against diabetes Abandoned CA2675511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85108306P 2006-10-10 2006-10-10
US60/851,083 2006-10-10
PCT/US2007/021678 WO2008045484A1 (en) 2006-10-10 2007-10-09 N-aryl pyrazole compounds for use against diabetes

Publications (1)

Publication Number Publication Date
CA2675511A1 true CA2675511A1 (en) 2008-04-17

Family

ID=39047570

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002675511A Abandoned CA2675511A1 (en) 2006-10-10 2007-10-09 N-aryl pyrazole compounds for use against diabetes

Country Status (12)

Country Link
US (1) US8022061B2 (OSRAM)
EP (1) EP2079728B1 (OSRAM)
JP (1) JP2010505957A (OSRAM)
AR (1) AR063240A1 (OSRAM)
AU (1) AU2007308154A1 (OSRAM)
CA (1) CA2675511A1 (OSRAM)
CL (1) CL2007002904A1 (OSRAM)
ES (1) ES2430821T3 (OSRAM)
MX (1) MX2009003821A (OSRAM)
PE (1) PE20080858A1 (OSRAM)
TW (1) TW200831491A (OSRAM)
WO (1) WO2008045484A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068171A1 (en) 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as jnk modulators
ES2551095T3 (es) * 2007-07-19 2015-11-16 Lundbeck, H., A/S Amidas heterocíclicas de 5 miembros y compuestos relacionados
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
AU2010218224B2 (en) 2009-02-26 2013-06-27 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2571359A4 (en) * 2010-05-20 2013-10-23 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
EA023254B1 (ru) 2010-05-27 2016-05-31 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2707323T3 (es) 2012-12-07 2019-04-03 Chemocentryx Inc Diazol lactamas
ES2648994T3 (es) * 2012-12-21 2018-01-09 Chemocentryx, Inc. Diazolamidas como antagonistas del receptor CCR1
CN103772282B (zh) * 2014-02-26 2015-09-23 上海毕得医药科技有限公司 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
CN118994191A (zh) * 2016-02-05 2024-11-22 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
WO2017176965A1 (en) 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HRP20220636T1 (hr) 2016-12-09 2022-07-22 Denali Therapeutics Inc. Spojevi korisni kao inhibitori ripk1
SG11202009179TA (en) * 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
WO2020007729A1 (en) 2018-07-04 2020-01-09 Boehringer Ingelheim International Gmbh Triazole benzamide derivatives as gpr142 agonists
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778433A (en) * 1969-04-18 1973-12-11 Sumitomo Chemical Co Process for producing benzodiazepine derivatives
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH04145081A (ja) 1990-10-06 1992-05-19 Kumiai Chem Ind Co Ltd ピラゾールカルボン酸誘導体及び除草剤
TW312694B (OSRAM) 1994-09-26 1997-08-11 Daiichi Seiyaku Co
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6169086B1 (en) * 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
CA2280515A1 (en) 1997-03-11 1998-09-17 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
JP4960565B2 (ja) 2000-05-12 2012-06-27 ジェンザイム コーポレーション ＴＮＦαシグナル伝達のモジュレータ
WO2002023986A1 (en) 2000-08-25 2002-03-28 Sankyo Company, Limited 4-acylaminopyrazole derivatives
US20040198758A1 (en) * 2001-08-17 2004-10-07 Rapado Liliana Parra N-heterocyclyl substituted thienyloxy-pyrimidines used as herbicides
EP1451160B1 (en) * 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
DE10234876A1 (de) * 2002-07-25 2004-02-05 Bayer Cropscience Gmbh 4-Trifluormethylpyrazolyl substituierte Pyridine und Pyrimidine
JP3774184B2 (ja) 2002-10-25 2006-05-10 株式会社フジクラ 光ファイバ心線テープ被覆除去具及び光ファイバ心線テープ被覆除去方法
WO2004098518A2 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Pyrazole-amide compounds useful as kinase inhibitors
JP2004339080A (ja) 2003-05-13 2004-12-02 Tokyo Institute Of Technology ピラゾ−ル誘導体を含有する高血圧治療剤
US6818631B1 (en) * 2003-08-15 2004-11-16 Nippon Soda Co. Ltd. Fungicidal pyrimidine derivatives
WO2005058883A1 (en) 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2008045664A2 (en) * 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents

Also Published As

Publication number Publication date
ES2430821T3 (es) 2013-11-21
MX2009003821A (es) 2009-05-25
PE20080858A1 (es) 2008-08-06
AR063240A1 (es) 2009-01-14
CL2007002904A1 (es) 2008-06-06
EP2079728B1 (en) 2013-09-25
TW200831491A (en) 2008-08-01
US8022061B2 (en) 2011-09-20
US20080153778A1 (en) 2008-06-26
AU2007308154A1 (en) 2008-04-17
JP2010505957A (ja) 2010-02-25
WO2008045484A1 (en) 2008-04-17
EP2079728A1 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
CA2675511A1 (en) N-aryl pyrazole compounds for use against diabetes
AU2011222531B2 (en) Nuclear transport modulatiors and uses thereof
CN108602776B (zh) 用作irak抑制剂的杂芳基化合物及其用途
US8741931B2 (en) Kinase inhibitors
EP2691399B1 (en) Thiazolopyrimidine compounds
AU2019382504B2 (en) Cyclic ureas
NZ551017A (en) Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
WO2009117421A2 (en) Heterocyclic modulators of gpr119 for treatment of disease
CA2836851A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
CN108290879A (zh) 用作irak抑制剂的杂芳基化合物及其用途
JP2010509231A (ja) プロテインキナーゼの阻害剤として有用なアミノピリジンおよびアミノピリミジン
AU2005321946A1 (en) Enzyme modulators and treatments
CA2465711A1 (en) Aminopyrimidines and pyridines
MX2014013751A (es) Piridazina y derivados de piridina como inhibidores de nampt.
JP2014141529A (ja) キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
MX2014013734A (es) Inhibidores de nampt.
CA2705583A1 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-.alpha.]imidazole-3-carboxylic acid amides
IL285246B1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
CA3172186A1 (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1
AU2009279611A1 (en) Aminopyridine kinase inhibitors
WO2015197188A1 (en) Pyrazolyl-based carboxamides as crac inhibitors
HK1125932A (en) Thiophene-carboxamides useful as inhibitors of protein kinases
HK1125107A (en) Aminopyrimidines useful as kinase inhibitors
HK1161230A (en) Protein kinase inhibitors
HK1130788A (en) Thiophene-carboxamides useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
FZDE Discontinued